Revenue segments as reported by the company.

Women’s Health

Biosimilars

Established Brands

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Acquired in-process research and development and milestones

Interest expense

Exchange losses (gains)

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Organon & Co

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Organon & Co reports strong Q4 earnings, eyes growth opportunities

Organon & Co's Q4 2022 earnings call highlighted robust financial performance, strategic initiatives in key segments, and a positive outlook for future growth. Despite challenges in China and market dynamics, the company remains focused on leveraging its strengths, addressing challenges, and capitalizing on growth opportunities to drive shareholder value and portfolio expansion.

Organon & Co reports solid Q1 performance and eyes growth opportunities

Organon & Co's Q1 2023 performance reflects revenue growth, margin improvement, and strategic investments in key franchises and medical devices.
The company's strengths lie in financial discipline, strong segment performance, and growth opportunities in fertility markets and biosimilars.
Challenges include inflationary pressures, competitive pricing scenarios, and the need to address loss of exclusivity and pricing dynamics.
Opportunities exist in expanding market presence in Asia Pacific, launching new products, and focusing on sustainable growth through financial prudence.

Organon & Co reports solid Q2 earnings, eyes growth opportunities

Organon & Co's Q2 2023 performance showed revenue growth, margin improvement, and strategic focus on key business segments.
Strengths in product differentiation, market positioning, and growth drivers position the company for continued success.
Challenges in revenue drivers, market expansion, and financial strategy require strategic adjustments for sustained growth.
Opportunities in Women's Health, biosimilar portfolio, and market penetration strategies offer avenues for future growth and market leadership.

Organon reports mixed Q3 results, eyes biosimilar growth opportunities

Organon's Q3 performance showed mixed results with challenges in women's health and biosimilar uptake, but stable growth in established brands.
The company is focusing on cost efficiency, portfolio optimization, and market expansion in biosimilars for future revenue growth.
Despite near-term challenges, Organon remains optimistic about its financial outlook, especially with opportunities in biosimilars and market expansion strategies.
Strategic shifts towards retail sector in China and product optimization are key focus areas for sustained growth and profitability.

Organon & Co reports solid Q4 earnings, eyes strategic growth

Organon's Q4 2023 earnings call showcased strong financials, strategic partnerships, and a focus on cost management. The company aims for low single-digit revenue growth in 2024 and $1 billion in free cash flow.

Organon & Co reports strong Q1 performance, eyes biosimilar growth

Organon & Co's Q1 2024 showcased robust revenue growth and strategic financial planning
Challenges include flat global fertility business and cautious outlook due to foreign exchange dynamics
Opportunities lie in expanding biosimilar market, margin expansion, and transformative deals

Organon & Co reports solid Q2 earnings, eyes franchise growth

Organon & Co's Q2 2024 performance reflects a mix of solid revenue growth and margin stability.
While facing challenges in certain regions and franchise segments, the company maintains a focus on growth.
Strategic opportunities lie in expanding key franchises, regulatory milestones, and operational efficiency.
Overall, Organon & Co remains optimistic about sustained revenue growth and financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viatris

Viatris and Organon are what can currently be described as "deep value plays" in the pharmaceutical sector. They face largely similar challenges, but on closer inspection are quite different companies. While I have already reported on Viatris' ever-changing portfolio, in this article I will take a closer look at Organon's portfolio and highlight the differences in strategy.

Don't Buy Viatris And Organon Just Because Of The Dividends

Organon has a solid portfolio driven by steady established brands and fast-growing Women's Health. Management is exercising balance sheet discipline by paying down debt all while maintaining a very well covered dividend.

Organon: Too Cheap To Ignore

Organon is a business I own - but only due to being awarded a significant number of shares, some of which I actually sold early on. I kept a stake. In this article, I'm going to follow a subscriber request and dive into what Organon might do for its shareholders, if you did not sell, or may be interested.

Is There Anything Organic Or Interesting About Organon?

JERSEY CITY, N.J.--( BUSINESS WIRE )--Organon (NYSE: OGN), a global women's healthcare company will release its fourth quarter and full year 2022 financial results on February 16, 2023, prior to the company's webcast and conference call scheduled for 8:30 a.m. EST.

Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 16, 2023

Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Organon (OGN) Beat Estimates Again in Its Next Earnings Report?

Organon & Co. (NYSE:OGN ) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 10:30 AM ET Company Participants Kevin Ali - CEO Matt Walsh - CFO Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody.

Organon & Co. (OGN) CEO Kevin Ali Presents at 41st Annual J.P. Morgan Healthcare Conference (Transcript)

JERSEY CITY, N.J.--( BUSINESS WIRE )--Organon (NYSE: OGN), a global women's healthcare company, today announced a strategic investment in Claria Medical, Inc. a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy. The agreement also grants Organon the option to acquire Claria Medical.

Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy

Albemarle

Biogen

Dollar General

DexCom

Enphase Energy

Etsy

First Solar

Halliburton

SolarEdge Technologies

Most S&P 500 investors lost nearly 20% this year. But plenty of moneymaking stocks jumped higher.

12 Stocks Turned $10,000 To $277,126 In 12 Months

JERSEY CITY, N.J.--( BUSINESS WIRE )--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10th, 2023 at 7:30 a.m. PT.

Organon To Present at the 41st Annual J.P. Morgan Healthcare Conference

JERSEY CITY, N.J.--( BUSINESS WIRE )--Organon (NYSE: OGN), a global women's healthcare company, today announced that Kirke Weaver has been appointed General Counsel and Corporate Secretary, and will continue as a member of Organon's executive leadership team, effective January 1, 2023. Mr. Weaver was named as the interim head of the Office of General Counsel and Corporate Secretary in July 2022.

Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary

Organon & Co. (NYSE:OGN ) Piper Sandler 34th Annual Healthcare Conference November 29, 2022 9:00 AM ET Company Participants Kevin Ali - Chief Executive Officer Matt Walsh - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler David Amsellem Okay. Good morning.

Organon & Co. (OGN) Presents at Piper Sandler 34th Annual Healthcare Conference

Organon's third-quarter results show third consecutive quarter of growth, with steady growth across divisions. From inception they have undergone a string of acquisitions and licensing deals that may allow further sales growth in 2023.

Organon: Q3 Results Show Promising Acquisitions But Mixed Portfolio Sales

JERSEY CITY, N.J.--( BUSINESS WIRE )--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29th, 2022 at 9:00 a.m. EST.

Organon To Present at the Piper Sandler 34th Annual Healthcare Conference

Organon & Co. (NYSE:OGN ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Jennifer Halchak – Vice President, Investor Relations Kevin Ali – Chief Executive Officer Matt Walsh – Chief Financial Officer Sandra Milligan – Head of R&D Conference Call Participants Terence Flynn – Morgan Stanley Umer Raffat – Evercore ISI David Amsellem – Piper Sandler Jason Gerberry – BofA Greg Fraser – Truist Securities Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Organon Third Quarter 2022 Earnings Conference Call.

Organon & Co. (OGN) Q3 2022 Earnings Call Transcript

Organon (OGN) delivered earnings and revenue surprises of 17.86% and 2.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Organon (OGN) Q3 Earnings and Revenues Top Estimates

Organon Reports Results for the Third Quarter Ended September 30, 2022

Organon To Report Third Quarter Results and Host Conference Call on November 3, 2022

DISH Network

Ford Motor Company

General Motors

Intel

Lumen Technologies

Mohawk Industries

Paramount Global

Progressive

Western Digital

Buying S&P 500 stocks on the cheap isn't a winning way to make money long term. But that doesn't stop some investors from trying anyway.

Analysts Think 9 Cheapest Of The Cheap Stocks Are Worth A Shot

Organon has seen a real struggle in its first year on its own as a publicly listed business. Lack of growth was anticipated, yet the extent of margin pressure has been unexpected.

Organon: What Is The Recipe?

INCHEON, Korea & JERSEY CITY, N.J.--(BUSINESS WIRE)--Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)

Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)

Organon & Co. (NYSE:OGN ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Jennifer Halchak - Vice President, Investor Relations Kevin Ali - Chief Executive Officer Matt Walsh - Chief Financial Officer Sandra Milligan - Head, R&D Conference Call Participants Jason Gerberry - Bank of America Umer Raffat - Evercore David Amsellem - Piper Sandler Greg Fraser - Truist Securities Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to Organon Second Quarter 2022 Earnings Conference Call.

Organon & Co. (OGN) CEO Kevin Ali on Q2 2022 Results - Earnings Call Transcript

Organon (OGN) delivered earnings and revenue surprises of 7.76% and 5.40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Organon (OGN) Surpasses Q2 Earnings and Revenue Estimates

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon reports results for the second quarter ended June 30, 2022

Organon Reports Results for the Second Quarter Ended June 30, 2022

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #contraception--Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate

Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #organon--Organon will release its second quarter 2022 financial results on 8/4/22, prior to the company's webcast and call scheduled for 8:30 a.m. EDT.

News for Organon & Co Stock (OGN)